|
|
|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS
|
|
|
|
|
|
|
Exploring Tumor Biomarkers in Urothelial Carcinoma: Insights and Advancements in Bladder Cancer Research
|
Chad Ritch, MD, MBA
Sam Chang and Chad Ritch discuss tumor biomarkers in urothelial carcinoma, exploring tissue-based and liquid-based markers. They highlight the limitations of cytology and the potential of RNA-based urinary biomarkers for non-invasive bladder cancer.
|
|
|
|
|
|
|
|
|
|
|
|
Exploring Genetic Biomarkers of Response to Enfortumab Vedotin in Advanced Urothelial Carcinoma: Analysis of UNITE Dataset
|
Vadim Koshkin, MD, and Tanya Jindal, BS, BA
Tanya Jindal and Vadim Koshkin join Petros Grivas to discuss their work to help identify potential biomarkers of response to enfortumab vedotin in patients with advanced urothelial carcinoma using a patient cohort in the UNITE dataset.
|
|
|
|
|
|
|
|
|
|
|
|
DNA Methylation Urine Biomarkers Test Shows Promise in Diagnosing Upper Tract Urothelial Cancer
|
Andrea Gallioli, MD, FEBU, and Angelo Territo, MD, Ph.D.
Andrea Gallioli and Angelo Territo join Sam Chang in a discussion on using DNA methylation markers to diagnose upper tract urothelial carcinoma in a single center prospective clinical trial.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SELECTED TOIPICAL CONTENT
|
|
|
|
|
| Biomarkers for Advanced Urothelial Carcinoma: Are We There Yet?
|
| Rana McKay, MD |
| Rana McKay discusses biomarkers for advanced urothelial carcinoma, highlighting two abstracts including “Genomic biomarkers in peripheral blood from patients enrolled in the JAVELIN Bladder 100 trial of avelumab first-line maintenance in advanced urothelial carcinoma” presented by Tom Powles and “PD-L1 expression on immune cells by SP142 co-localizes with dendritic cells and is associated with improved OS with atezolizumab in patients with untreated metastatic urothelial cancer” presented by Enrique Pulido.
|
|
|
|
|
|
| Neoadjuvant Pembrolizumab May Result in Long-Term Outcome Improvement in Biomarker-Unselected Patients With Muscle-Invasive Bladder Cancer: Updated results from PURE-01
|
| Luigi Nocera, MD
|
| Luigi Nocera provides updated outcomes results of PURE-01, an open-label, single-arm, phase 2 study, where cT2-4aN0M0 MIBC patients received three courses of 200 mg pembrolizumab preceding radical cystectomy. The aim of this report is to present updated results on recurrence-free survival and overall survival at longer follow-up.
|
|
|
|
|
|
|
|
|
|
|
| Biomarkers of Response to Enfortumab Vedotin in Patients with Advanced Urothelial Carcinoma: Analysis of the UNITE Study
|
| Tanya Jindal, BS, BA
|
| Tanya Jindal presents on behalf of the UNITE study collaborators, an analysis to identify potential biomarkers of response to enfortumab vedotin (EV) in patients with advanced urothelial carcinoma. In this large, multi-site, retrospective cohort of patients with advanced UC, they identified several potential biomarkers associated with differential outcomes to EV. These findings, upon external validation, may help inform clinical decision making and potential therapy sequencing with available ADCs.
|
|
|
|
|
|
| Discussant: Advanced Urothelial Carcinoma: Striking a Balance of Efficacy and Safety
|
| Andrea Necchi, MD
|
| In this presentation, Andrea Necchi discusses 3 oral abstracts with an emphasis on "Striking a Balance between Efficacy and Safety" for advanced urothelial carcinoma. These abstracts revolve around various therapeutic approaches, including immunotherapy and targeted therapies, and their impact on patient outcomes. Dr. Necchi emphasizes the importance of personalized treatment decisions, considering patient characteristics, tumor biomarkers, and potential side effects to optimize efficacy while maintaining patient safety.
|
|
|
|
|
|
| Biomarkers of Response to Sacituzumab Govitecan and Efficacy After Treatment with Enfortumab Vedotin in Advanced Urothelial Carcinoma: Analysis of the UNITE Study
|
| Tanya Jindal, BS, BA |
| Tanya Jindal discusses a study which analyzed the UNITE trial data and identified potential biomarkers that could predict response to these treatments. The findings suggest that specific genetic alterations and high tumor mutational burden may be associated with better treatment outcomes, providing valuable insights for personalized therapy selection in patients with advanced urothelial carcinoma.
|
|
|
|
|
|
| Genomic Biomarkers in Peripheral Blood From Patients Enrolled in the JAVELIN Bladder 100 Trial of Avelumab First-line Maintenance in Advanced Urothelial Carcinoma
|
| Thomas B. Powles, MBBS, MRCP, MD
|
| In this presentation. Thomas Powles discusses work which evaluated avelumab as first-line maintenance therapy in advanced urothelial carcinoma. The study aimed to identify potential genomic biomarkers that could predict treatment response and outcomes.
|
|
|
|
|
|
|
|
|
|
|
|
